Precision Underlines US FDA’s 2025 Cancer, Neuroscience Candidates

 
• By Bridget Silverman
  
Increasingly precise and targeted interventions in disease biology are driving the highly active oncology and neuroscience drug pipelines. (Shutterstock)

More from Pink Sheet Perspectives

More from Regulatory Trackers